Proxygen, a leader in the discovery and development of molecular glue degraders, announced a multi-year research collaboration and license agreement with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) to jointly identify and develop molecular glue degraders against multiple therapeutic targets.